香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 持續關連交易 重續持續關連交易 重續持續關連交易 茲提述本公司(i)日期為2023年3月30日之公告，內容有關（其中包括）訂立2023 年金融服務協議；(ii)日期為2023年10月31日之公告，內容有關（其中包括）訂 立2023年供應協議、2023年購買協議、2023年租賃協議、2023年碳-14供應協 議、2023年鈷-60供應協議、2023年諮詢協議及2023年工程建設服務框架協議， 及(iii)日期為2024年8月30日之公告，內容有關（其中包括）修訂2023年工程建 設服務框架協議、2023年購買協議及2023年供應協議項下的年度上限。 由於該等協議均將於2025年12月31日屆滿，為繼續該等協議項下進行的各項交 易，董事會已決議重 ...

此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 中国同辐(01763)发布公告，2025年12月10日，原子高科股份有限公司(本公司旗下一间于全国中小企业 股份转让系统上市的附属公司)与北京师范大学在北京举办科技成果转化签约暨产学研合作交流会，共 同签署了氟[18F]贝他嗪项目《专利转让协议》与《产学研合作协议》。 氟[18F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权 的一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著 降低的特点，优于已获FDA批准的同类产品。 ...

智通财经APP讯，中国同辐(01763)发布公告，2025年12月10日，原子高科股份有限公司(本公司旗下一 间于全国中小企业股份转让系统上市的附属公司)与北京师范大学在北京举办科技成果转化签约暨产学 研合作交流会，共同签署了氟[F]贝他嗪项目《专利转让协议》与《产学研合作协议》。 此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 氟[F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权的 一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著降 低的特点，优于已获FDA批准的同类产品。 ...

格隆汇12月11日丨中国同辐(01763.HK)公告，以下公告的中文原稿由中国同辐股份有限公司旗下一间于 全国中小企业股份转让系统上市的附属公司，原子高科股份有限公司(股份代号：430005)于中国境内发 布。 氟[F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权的 一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著降 低的特点，优于已获FDA批准的同类产品。 此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 2025年12月10日，原子高科股份有限公司(以下简称"原子高科")与北京师范大学(以下简称"北师大")在 北京举办科技成果转化签约暨产学研合作交流会，共同签署了氟[18F]贝他嗪项目《专利转让协议》与 《产学研合作协议》。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 於其他海外監管市場發佈的公告 中國同輻附屬公司與北京師範大學簽署氟[18F]貝他嗪一類創新 核藥專利轉讓協議及產學研項目合作協議 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁建民先生及常晉峪女士；及獨立非執行 董事潘昭國先生、陳景善女士、盧闖先生及安銳先生。 公告编号：2025-059 证券代码：430005 证券简称：原子高科 主办券商：广发证券 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈 ...

Core Insights - The Chinese nuclear technology application industry is transitioning from a "follower" to a "leader" position, particularly in the nuclear medical field, with significant advancements in the supply of key isotopes and domestic market share of radiation therapy equipment [1][2][3] - The market for radioactive drugs is projected to grow from 9.3 billion yuan in 2025 to 26 billion yuan by 2030, indicating strong growth potential in the nuclear medical sector [3] - The "Nuclear Technology Application Industry High-Quality Development Three-Year Action Plan (2024-2026)" aims for the industry to achieve a direct economic output of 400 billion yuan by 2026, with a target of 600 billion yuan by the end of the 14th Five-Year Plan [3][5] Achievements - The successful production of Lu-177 isotope by Qinshan Nuclear Power, which is expected to meet domestic market needs for targeted cancer therapies, marks a significant milestone in self-sufficient isotope supply [1][4] - Over 90 radiation therapy devices have been approved for market use by the National Medical Products Administration, with more than 70% being domestic brands, reducing reliance on imports [2] - The development pipeline for new radioactive drugs has accelerated, with over 200 candidates entering clinical trials, enhancing treatment options for cancer [2] Challenges - The industry faces risks related to single-point dependency on key isotopes and insufficient elasticity in the supply chain, which could jeopardize stability in nuclear medicine and industrial applications [4] - There is a lack of understanding among small and medium enterprises regarding national support policies, leading to difficulties in seizing development opportunities [4] - Issues such as insufficient investment in basic research, weak pilot testing for technology transfer, and imbalanced regional development are hindering overall industry progress [4] Strategic Initiatives - The "Strong Chain Action Plan" was launched to address existing challenges and promote a systematic upgrade of the nuclear technology application industry, involving collaboration among state-owned enterprises, research institutions, and private companies [5][6] - The plan emphasizes a collaborative approach to enhance the entire industry chain, ensuring the stability of domestic isotope supply and fostering innovation through cross-sector integration [6] - The initiative aims to create industrial clusters in key regions to address developmental imbalances and stimulate growth across the industry [6]

Core Insights - The integration of AI and nuclear technology is driving a significant transformation in the nuclear technology application industry, which has a market size of several hundred billion yuan and an annual growth rate exceeding 15% [1] - This convergence is expected to enhance efficiency, precision, and expand application scenarios across various sectors of the national economy [1] Group 1: AI and Nuclear Technology in Public Safety - AI-enabled nuclear technology is revolutionizing public safety, particularly in security checks, by improving efficiency and convenience for travelers [2] - The intelligent security system developed by Tongfang Weishi for Hong Kong International Airport exemplifies this integration, utilizing AI algorithms for efficient collaboration among various security devices [2] - The new security solution is projected to simplify the security process significantly by 2026, allowing travelers to keep liquids and gels in their bags, thus enhancing the overall experience [2] Group 2: Food Safety and Quality Enhancement - The fusion of AI and nuclear technology is addressing traditional challenges in food safety, particularly in non-destructive testing methods [3] - The durian quality CT detection system represents a significant advancement, allowing for non-invasive inspection of durians, thus eliminating the "blind box" market issue [3] - This technology boasts an accuracy rate exceeding 98%, which is 40 times more accurate than manual inspections [3] Group 3: Advancements in New Energy Sector - The integration of AI and nuclear technology is also showing strong potential in the new energy sector, particularly in lithium battery quality assurance [4] - Tongfang Weishi's technology can identify micron-level defects, thereby reducing the risk of battery fires and enhancing safety [4] - Collaborations with leading lithium battery manufacturers like CATL highlight the practical applications of this technology [4] Group 4: Market Expansion and Future Directions - The new industrialization strategy encompasses multiple dimensions, including technology, manufacturing, and quality, providing a broad market space for nuclear technology applications [5] - Challenges such as insufficient industrialization and innovation capabilities, as well as a shortage of interdisciplinary talent, need to be addressed for future development [6] - Key strategic directions include enhancing top-level planning, implementing action plans for high-quality development, and fostering innovation through collaborative efforts [6] Group 5: Key Companies in Nuclear Technology - Tongfang Co., Ltd. (600100) is a leader in security checks, providing solutions that integrate radiation imaging and AI for various applications [7] - China General Nuclear Power Corporation (000881) focuses on non-power nuclear technology applications, including industrial irradiation and medical accelerators [7] - China Nuclear Power (601985) operates multiple nuclear power plants and leverages group resources for nuclear technology applications [7]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國同輻股份有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01763 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 79,968,800 | RMB | | 1 | RMB | | 79,968,800 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 79,968,800 | RMB | | 1 | RMB | | 79,968,800 | | 2. 股份分類 ...

Core Viewpoint - China Tongfu (01763) has signed a strategic cooperation agreement with China National Nuclear Corporation Capital Holdings Co., Ltd. to enhance the integration of the nuclear technology application industry chain and address key technological bottlenecks [1] Group 1: Strategic Cooperation - The agreement focuses on resource sharing and complementary advantages to promote the integration of the nuclear technology application industry chain [1] - Both parties aim to collaborate deeply in areas such as mergers and acquisitions, new company establishment, equity investment, and securities business [1] - The cooperation seeks to create a new pattern of coordinated development between technology and finance, as well as industry and finance [1] Group 2: Goals and Objectives - The core objectives include breaking through critical technological bottlenecks and cultivating new productive forces [1] - The partnership is designed to empower China Tongfu to achieve high-quality development through financial capital [1]

Core Insights - China Tongfu (01763.HK) signed a strategic cooperation agreement with China National Nuclear Corporation Capital Holdings Co., Ltd. at the second Nuclear Technology Application Industry Chain Co-Chain Action Conference on November 27 [1] Group 1: Strategic Cooperation - The agreement focuses on promoting the integration of the nuclear technology application industry chain and overcoming key technological bottlenecks [1] - The collaboration aims to cultivate new productive forces through resource sharing and complementary advantages [1] Group 2: Areas of Collaboration - The partnership will involve deep cooperation in areas such as mergers and acquisitions, establishment of new companies, equity investments, and securities business [1] - The goal is to create a new pattern of coordinated development between technology and finance, as well as industry and finance [1] Group 3: Development Goals - The strategic cooperation is designed to empower China Tongfu with financial capital to achieve high-quality development [1]